Clinical Trials
43 trialsA Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
MK-4700-001
Merck Sharp & Dohme LLC
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Innate Pharma
LB-LR1109
LG Chem
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Pfizer
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
MacroGenics
AM-003
University of Virginia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
PDL1x41BB
Inhibrx Biosciences, Inc
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
RemeGen Co., Ltd.
DUET-3
Xencor, Inc.
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
University of California, San Francisco
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
TORCH
University of Florida
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America, Inc.
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
DUET-4
Xencor, Inc.
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
Herlev Hospital
NEO
Advaxis, Inc.
DUET-2
Xencor, Inc.
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
EMD Serono
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Pfizer
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation